Esansiyel Trombositemi Hastalarında JAK2-V617F Mutasyonu ile Klinik Sonlanım Belirteçleri Arasındaki Ilişki

Abstract

The prognostic value of JAK2 - V617F mutation remains unclear in essential thrombocythemia (ET). However, leukocytosis, anemia, thrombocytosis, advanced age, and splenomegaly are all associated with poor clinical outcomes, such as thrombosis, hemorrhage, and short life expectancy. JAK2 mutation may be related to these parameters and may establish prognostic value in this regard. Therefore, we investigated the relationship between JAK2 mutation and these predictors of poor prognosis. This retrospective, cross-sectional study is conducted in archives of a Hematology Clinic in an Education Hospital at 2013. All p atients who have been diagnosed with ET and have JAK2 mutation analysis results, are included to the study. Diagnosis of ET was made according to the World Health Organization (WHO) Diagnostic Criteria for ET. Demographic characteristics, complete blood counts, abdominal ultrasounds and JAK2 mutation analyses are collected from patient files for 84 patients. The relationship between JAK2 mutation and age, sex, hemoglobin, leukocyte, thrombocyte counts, and splenomegaly is analyzed by using appropriate statistical analysis. In total, 54.7% of patients with ET tested positive for the JAK2 mutation. Patients with JAK2 mutation had higher leukocyte levels ( p < 0.001), higher hemoglobin levels ( p = 0.014), and splenomegaly ( p < 0.001). There was no relationship between JAK2 mutation and age, sex, thrombocyte counts or anemia. The JAK2 mutation is related to leukocytosis and splenomegaly, which are known to be thrombotic risk factors. Therefore, JAK2 mutation may have a prognostic value and warrants further research with clinical outcomes.